Issue The Evolving Pharmaceutical Supply Chain

Current Issue: Q3 2020

The Outsourcing Issue

The Evolving Pharmaceutical Supply Chain

Our Q3 edition focuses on the evolution of outsourcing providers and innovations driving the future of healthcare. Experts from all facets of the industry discuss ongoing impacts from the COVID-19 pandemic, particularly to the supply chain, as well as topics spanning decentralized clinical trials, organ-on-a-chip technology, and increasing speed to the clinic.

Also In This Issue

Lipid Excipients

Successful Drug Development with Synthetic Lipids: Critical Aspects and Strategies (Clone)

Lipid-based drug delivery systems offer several advantages, including improving the stability, solubility, bioavailability, and toxicity profiles of active pharmaceutical ingredients (APIs). It is essential to select the optimal lipid excipients with the appropriate characteristics for each specific API and application and to ensure that they can be produced using high-quality production methods that are scalable […]

Cover story

Restarting a Manufacturing Campus and Revitalizing a Community

In 2017, Federal Equipment Company learned that a modern pharmaceutical manufacturing campus located in Huntsville, Alabama, was on the real estate market after its owner, Par Pharmaceuticals, an Endo International company, shut down operations. While our team has purchased entire facilities in the past, liquidated the equipment, and sold the facilities to other entities, we […]

Nice Insight Overview

The Benefits of Expanding OSD Capacity

NICE INSIGHT OVERVIEW: Oral Solid Dose Oral solid dosage (OSD) remains the predominant form of administration for drugs on the market and constitutes the majority of drugs in the industry pipeline. Several factors in the market, from increasing API complexity to technology development, are driving greater interest in contract development and manufacturing organizations (CDMOs) for […]

Equipment

Reshoring a Nation’s API and Pharmaceutical Production

The pharmaceutical industry has embraced a global supply chain model for decades, seeking cost advantages made available by offshore manufacturing of starting materials, intermediates, and active pharmaceutical ingredients (APIs), particularly in Asia. However, a variety of concerns — notably underscored by supply chain disruptions driven by the COVID-19 pandemic — are pushing companies to redraw […]

Microbiome CDMO

Extensive Experience Is Crucial to Speed to the Clinic and Market for Live Biotherapeutic Products

As more microbiome-based therapies progress through the clinic toward approval for market launch, concerns over the lack of outsourcing capacity for process development and commercial manufacturing of live biotherapeutic products (LBPs) are increasing. Arranta Bio has more than a decade of experience in the development and tech transfer of LBPs under GMP conditions. Our actALIVE™ […]

Vaccine Distribution

Anticipating the Logistics of a COVID-19 Vaccination Effort

Over 24 million cases of COVID-19 have been confirmed worldwide, including more than 800,000 deaths. There is a dire need for therapeutics and vaccines to fight the pandemic, and the biopharmaceutical industry has been working at a furious pace to develop effective products. While the accelerated development and manufacture of COVID-19 vaccines is a daunting […]

Leadership

A CEO’s Perspective: Positioning a CDMO for Significant Growth

Avid Bioservices has reached a critical juncture and is poised for significant growth. New President and CEO Nicholas Green is excited to work with Avid’s board of directors, management team, and employees to take the company to the next level. Reaching Critical Mass To be truly successful, contract development and manufacturing organizations (CDMOs) must build […]

Parenterals

Trends Shaping the Dynamic Market for Parenterals

Demand for parenteral drugs continues to increase as the overall drug market expands and new therapies for both chronic and rare diseases enter the pipeline. Manufacturers are faced with increasing complexity, not only because of the drug substances but also due to formulations, patient-centric delivery technologies, and regulatory requirements, which are all further complicated by […]

Integrated CDMO

Building an Integrated and Effective CDMO from the Ground Up

CDMOs are a key link in the pharmaceutical supply chain, but most do not meet the expectations of their pharma customers. TriRx is building an integrated CDMO designed to fill the gap and be a reliable source of supply well into the future. Bridging the Outsourcing Gap CDMOs have become critical partners in the pharmaceutical […]

Recombinant Proteins

Innovation and Flexibility Drive Success During the COVID-19 Pandemic

Grifols Recombinant Protein CDMO is focused on the same flexibility and problem-solving spirit we use daily to rapidly produce custom proteins to battle the current pandemic. In these exceptional circumstances, what we do matters more than ever. At Grifols Recombinant Protein CDMO, we produce recombinant proteins for further manufacture that are used in assays to […]

Past Issues

View all Past Issues

The Breakthrough Issue

View Issue »

Issue #4 | Volume #5 | Q4 2019

Market Landscape

View Issue »

Issue #1 | Volume #3 | Q1 2017

The Next-Generation Issue

View Issue »

Issue #2 | Volume #6 | Q2 2020

The Outsourcing Issue

View Issue »

Issue #3 | Volume #6 | Q3 2020